Welcome to our dedicated page for BioCryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.
BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.
The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.
In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.
BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.
For more information, please visit www.biocryst.com or follow them on LinkedIn.
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported new findings from the APeX-S clinical trial on ORLADEYO (berotralstat), showcasing sustained attack-free days for patients over 96 weeks. Presented at the C1-inhibitor Deficiency & Angioedema Workshop in Budapest, the trial demonstrated a reduction in hereditary angioedema (HAE) attack rates across various demographics, including age and gender. This oral medication is designed for patients aged 12 and older, and the results affirm its safety and effectiveness, with mild adverse events reported. Patients aged 12-17 maintained an attack-free status 97% of the time, while older patients also showed significant improvements in attack reduction rates. The commitment to expand ORLADEYO's accessibility to HAE patients globally remains robust.
BioCryst Pharmaceuticals (BCRX) announced it will report its first quarter 2023 financial results on May 3, 2023. The management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the live call by dialing the designated numbers or via the company's investor website. BioCryst focuses on developing novel oral medicines for rare diseases, with its product ORLADEYO (berotralstat) approved in the U.S. and several international markets. In addition, the company is advancing programs targeting the complement system, including the clinical development of BCX10013. More details are available on their website.
BioCryst Pharmaceuticals (BCRX) announced a $450 million financing deal from Pharmakon Advisors. The company will initially draw $300 million, expecting to receive around $26 million net proceeds after repaying debts. This new five-year credit facility carries an interest rate of SOFR + 7.00%, with an option to defer cash interest payments for the first six quarters.
With this financing, BioCryst extends its repayment timeline from 2025 to 2028, aligning with anticipated peak revenues of $1 billion for its drug ORLADEYO. The agreement significantly improves financial terms from a previous credit arrangement, reducing reliance on capital markets. Pharmakon Advisors emphasizes its support for BioCryst’s continued growth and commitment to rare disease treatments.
BioCryst Pharmaceuticals (BCRX) announced its participation in several upcoming investor conferences. The company will present at:
- The 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET
- The BofA Securities 2023 Health Care Conference in Las Vegas on May 10 at 6:00 p.m. ET
- The JMP Securities Life Sciences Conference in New York on May 16 at 2:30 p.m. ET
- The RBC Capital Markets Global Healthcare Conference in New York on May 17 at 8:00 a.m. ET
Live audio webcasts and replays will be accessible in the Investors & Media section of BioCryst’s website. Known for developing oral medicines for rare diseases, BioCryst's ORLADEYO (berotralstat) is already approved in the U.S. and other markets.
FAQ
What is the current stock price of BioCryst Pharmaceuticals (BCRX)?
What is the market cap of BioCryst Pharmaceuticals (BCRX)?
What is BioCryst Pharmaceuticals' main product?
Where is BioCryst Pharmaceuticals headquartered?
What therapeutic areas does BioCryst Pharmaceuticals focus on?
What recent achievements has BioCryst Pharmaceuticals reported?
How does ORLADEYO® work?
What is the pipeline of BioCryst Pharmaceuticals?
Who are BioCryst Pharmaceuticals' partners?
What is the company's approach to drug development?
What are some of the challenges BioCryst Pharmaceuticals addresses?
How can I stay updated on BioCryst Pharmaceuticals' latest news?
